Quoin Pharmaceuticals said the FDA cleared its IND for QRX003 to treat Peeling Skin Syndrome, enabling the company to start a Phase 2 study. The approval is a meaningful regulatory milestone that de-risks early development and supports the next clinical phase. Market impact is likely limited near term unless additional trial details or timelines are provided.
Quoin Pharmaceuticals said the FDA cleared its IND for QRX003 to treat Peeling Skin Syndrome, enabling the company to start a Phase 2 study. The approval is a meaningful regulatory milestone that de-risks early development and supports the next clinical phase. Market impact is likely limited near term unless additional trial details or timelines are provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
